ID   UBE2S_HUMAN             Reviewed;         222 AA.
AC   Q16763; Q9BTC1;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   10-OCT-2002, sequence version 2.
DT   10-MAY-2017, entry version 167.
DE   RecName: Full=Ubiquitin-conjugating enzyme E2 S;
DE            EC=2.3.2.23 {ECO:0000269|PubMed:19820702, ECO:0000269|PubMed:19822757, ECO:0000269|PubMed:20061386};
DE   AltName: Full=E2 ubiquitin-conjugating enzyme S;
DE   AltName: Full=E2-EPF;
DE   AltName: Full=Ubiquitin carrier protein S;
DE   AltName: Full=Ubiquitin-conjugating enzyme E2-24 kDa;
DE   AltName: Full=Ubiquitin-conjugating enzyme E2-EPF5;
DE   AltName: Full=Ubiquitin-protein ligase S;
GN   Name=UBE2S; Synonyms=E2EPF; ORFNames=OK/SW-cl.73;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Foreskin;
RX   PubMed=1379239;
RA   Liu Z., Diaz L.A., Haas A.L., Giudice G.J.;
RT   "cDNA cloning of a novel human ubiquitin carrier protein. An antigenic
RT   domain specifically recognized by endemic pemphigus foliaceus
RT   autoantibodies is encoded in a secondary reading frame of this human
RT   epidermal transcript.";
RL   J. Biol. Chem. 267:15829-15835(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Colon adenocarcinoma;
RA   Shichijo S., Itoh K.;
RT   "Identification of immuno-peptidmics that are recognized by tumor-
RT   reactive CTL generated from TIL of colon cancer patients.";
RL   Submitted (MAY-2001) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J.,
RA   Lamerdin J.E., Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M.,
RA   Aerts A., Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E.,
RA   Caenepeel S., Carrano A.V., Caoile C., Chan Y.M., Christensen M.,
RA   Cleland C.A., Copeland A., Dalin E., Dehal P., Denys M., Detter J.C.,
RA   Escobar J., Flowers D., Fotopulos D., Garcia C., Georgescu A.M.,
RA   Glavina T., Gomez M., Gonzales E., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Ho I., Huang W., Israni S., Jett J., Kadner K., Kimball H.,
RA   Kobayashi A., Larionov V., Leem S.-H., Lopez F., Lou Y., Lowry S.,
RA   Malfatti S., Martinez D., McCready P.M., Medina C., Morgan J.,
RA   Nelson K., Nolan M., Ovcharenko I., Pitluck S., Pollard M.,
RA   Popkie A.P., Predki P., Quan G., Ramirez L., Rash S., Retterer J.,
RA   Rodriguez A., Rogers S., Salamov A., Salazar A., She X., Smith D.,
RA   Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., Ustaszewska A.,
RA   Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., Dubchak I.,
RA   Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Colon, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   FUNCTION, AND INTERACTION WITH VHL.
RX   PubMed=16819549; DOI=10.1038/nm1440;
RA   Jung C.R., Hwang K.S., Yoo J., Cho W.K., Kim J.M., Kim W.H., Im D.S.;
RT   "E2-EPF UCP targets pVHL for degradation and associates with tumor
RT   growth and metastasis.";
RL   Nat. Med. 12:809-816(2006).
RN   [6]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [7]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [8]
RP   FUNCTION, CATALYTIC ACTIVITY, AND PATHWAY.
RX   PubMed=19820702; DOI=10.1038/ncb1983;
RA   Garnett M.J., Mansfeld J., Godwin C., Matsusaka T., Wu J., Russell P.,
RA   Pines J., Venkitaraman A.R.;
RT   "UBE2S elongates ubiquitin chains on APC/C substrates to promote
RT   mitotic exit.";
RL   Nat. Cell Biol. 11:1363-1369(2009).
RN   [9]
RP   FUNCTION, CATALYTIC ACTIVITY, PATHWAY, INTERACTION WITH CDC20 AND FZR,
RP   UBIQUITINATION, AND MUTAGENESIS OF CYS-95.
RX   PubMed=19822757; DOI=10.1073/pnas.0907887106;
RA   Williamson A., Wickliffe K.E., Mellone B.G., Song L., Karpen G.H.,
RA   Rape M.;
RT   "Identification of a physiological E2 module for the human anaphase-
RT   promoting complex.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:18213-18218(2009).
RN   [10]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=20061386; DOI=10.1074/jbc.M109.089003;
RA   David Y., Ziv T., Admon A., Navon A.;
RT   "The E2 ubiquitin-conjugating enzymes direct polyubiquitination to
RT   preferred lysines.";
RL   J. Biol. Chem. 285:8595-8604(2010).
RN   [11]
RP   FUNCTION, AND MUTAGENESIS OF CYS-95.
RX   PubMed=20622874; DOI=10.1038/nsmb.1873;
RA   Bremm A., Freund S.M., Komander D.;
RT   "Lys11-linked ubiquitin chains adopt compact conformations and are
RT   preferentially hydrolyzed by the deubiquitinase Cezanne.";
RL   Nat. Struct. Mol. Biol. 17:939-947(2010).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-173, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (1.93 ANGSTROMS) OF 1-156.
RG   Structural genomics consortium (SGC);
RT   "Crystal structure of human ubiquitin-conjugating enzyme E2S.";
RL   Submitted (FEB-2009) to the PDB data bank.
CC   -!- FUNCTION: Accepts ubiquitin from the E1 complex and catalyzes its
CC       covalent attachment to other proteins. Catalyzes 'Lys-11'-linked
CC       polyubiquitination. Acts as an essential factor of the anaphase
CC       promoting complex/cyclosome (APC/C), a cell cycle-regulated
CC       ubiquitin ligase that controls progression through mitosis. Acts
CC       by specifically elongating 'Lys-11'-linked polyubiquitin chains
CC       initiated by the E2 enzyme UBE2C/UBCH10 on APC/C substrates,
CC       enhancing the degradation of APC/C substrates by the proteasome
CC       and promoting mitotic exit. Also acts by elongating ubiquitin
CC       chains initiated by the E2 enzyme UBE2D1/UBCH5 in vitro; it is
CC       however unclear whether UBE2D1/UBCH5 acts as an E2 enzyme for the
CC       APC/C in vivo. Also involved in ubiquitination and subsequent
CC       degradation of VHL, resulting in an accumulation of HIF1A. In
CC       vitro able to promote polyubiquitination using all 7 ubiquitin Lys
CC       residues, except 'Lys-48'-linked polyubiquitination.
CC       {ECO:0000269|PubMed:16819549, ECO:0000269|PubMed:19820702,
CC       ECO:0000269|PubMed:19822757, ECO:0000269|PubMed:20061386,
CC       ECO:0000269|PubMed:20622874}.
CC   -!- CATALYTIC ACTIVITY: S-ubiquitinyl-[E1 ubiquitin-activating
CC       enzyme]-L-cysteine + [E2 ubiquitin-conjugating enzyme]-L-cysteine
CC       = [E1 ubiquitin-activating enzyme]-L-cysteine + S-ubiquitinyl-[E2
CC       ubiquitin-conjugating enzyme]-L-cysteine. {ECO:0000255|PROSITE-
CC       ProRule:PRU00388, ECO:0000255|PROSITE-ProRule:PRU10133,
CC       ECO:0000269|PubMed:19820702, ECO:0000269|PubMed:19822757,
CC       ECO:0000269|PubMed:20061386}.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC       {ECO:0000255|PROSITE-ProRule:PRU00388,
CC       ECO:0000269|PubMed:19820702, ECO:0000269|PubMed:19822757}.
CC   -!- SUBUNIT: Component of the APC/C complex. Interacts with CDC20,
CC       FZR1/CDH1 and VHL. {ECO:0000269|PubMed:16819549,
CC       ECO:0000269|PubMed:19822757}.
CC   -!- PTM: Autoubiquitinated by the APC/C complex during G1, leading to
CC       its degradation by the proteasome. {ECO:0000269|PubMed:19822757}.
CC   -!- SIMILARITY: Belongs to the ubiquitin-conjugating enzyme family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00388}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M91670; AAA58446.1; -; mRNA.
DR   EMBL; AB062397; BAB93484.1; -; mRNA.
DR   EMBL; AC020922; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC004236; AAH04236.1; -; mRNA.
DR   EMBL; BC007554; AAH07554.1; -; mRNA.
DR   EMBL; BC065364; AAH65364.1; -; mRNA.
DR   CCDS; CCDS33114.1; -.
DR   RefSeq; NP_055316.2; NM_014501.2.
DR   UniGene; Hs.396393; -.
DR   PDB; 1ZDN; X-ray; 1.93 A; A/B=1-156.
DR   PDB; 5BNB; X-ray; 2.49 A; A/B/C/D=1-156.
DR   PDB; 5L9T; EM; 6.40 A; T=1-222.
DR   PDBsum; 1ZDN; -.
DR   PDBsum; 5BNB; -.
DR   PDBsum; 5L9T; -.
DR   ProteinModelPortal; Q16763; -.
DR   SMR; Q16763; -.
DR   BioGrid; 118150; 66.
DR   DIP; DIP-52784N; -.
DR   IntAct; Q16763; 11.
DR   MINT; MINT-6774405; -.
DR   STRING; 9606.ENSP00000264552; -.
DR   iPTMnet; Q16763; -.
DR   PhosphoSitePlus; Q16763; -.
DR   BioMuta; UBE2S; -.
DR   DMDM; 23829978; -.
DR   EPD; Q16763; -.
DR   MaxQB; Q16763; -.
DR   PaxDb; Q16763; -.
DR   PeptideAtlas; Q16763; -.
DR   PRIDE; Q16763; -.
DR   DNASU; 27338; -.
DR   Ensembl; ENST00000264552; ENSP00000264552; ENSG00000108106.
DR   GeneID; 27338; -.
DR   KEGG; hsa:27338; -.
DR   UCSC; uc002qkx.2; human.
DR   CTD; 27338; -.
DR   DisGeNET; 27338; -.
DR   GeneCards; UBE2S; -.
DR   H-InvDB; HIX0039201; -.
DR   HGNC; HGNC:17895; UBE2S.
DR   HPA; CAB015228; -.
DR   HPA; HPA057150; -.
DR   MIM; 610309; gene.
DR   neXtProt; NX_Q16763; -.
DR   OpenTargets; ENSG00000108106; -.
DR   PharmGKB; PA134904441; -.
DR   eggNOG; KOG0423; Eukaryota.
DR   eggNOG; COG5078; LUCA.
DR   GeneTree; ENSGT00730000110565; -.
DR   HOGENOM; HOG000233455; -.
DR   HOVERGEN; HBG063308; -.
DR   InParanoid; Q16763; -.
DR   KO; K10583; -.
DR   OrthoDB; EOG091G0USF; -.
DR   PhylomeDB; Q16763; -.
DR   TreeFam; TF101120; -.
DR   BRENDA; 2.3.2.B6; 2681.
DR   Reactome; R-HSA-8866652; Synthesis of active ubiquitin: roles of E1 and E2 enzymes.
DR   Reactome; R-HSA-983168; Antigen processing: Ubiquitination & Proteasome degradation.
DR   SignaLink; Q16763; -.
DR   UniPathway; UPA00143; -.
DR   ChiTaRS; UBE2S; human.
DR   EvolutionaryTrace; Q16763; -.
DR   GenomeRNAi; 27338; -.
DR   PRO; PR:Q16763; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; ENSG00000108106; -.
DR   CleanEx; HS_UBE2S; -.
DR   ExpressionAtlas; Q16763; baseline and differential.
DR   Genevisible; Q16763; HS.
DR   GO; GO:0005680; C:anaphase-promoting complex; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0061631; F:ubiquitin conjugating enzyme activity; IDA:MGI.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IBA:GO_Central.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IBA:GO_Central.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; IDA:UniProtKB.
DR   GO; GO:0031145; P:anaphase-promoting complex-dependent catabolic process; IDA:UniProtKB.
DR   GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
DR   GO; GO:0006464; P:cellular protein modification process; TAS:ProtInc.
DR   GO; GO:0010458; P:exit from mitosis; IDA:UniProtKB.
DR   GO; GO:0010994; P:free ubiquitin chain polymerization; IDA:UniProtKB.
DR   GO; GO:1904668; P:positive regulation of ubiquitin protein ligase activity; IDA:UniProtKB.
DR   GO; GO:0070979; P:protein K11-linked ubiquitination; IDA:UniProtKB.
DR   GO; GO:0044314; P:protein K27-linked ubiquitination; IDA:UniProtKB.
DR   GO; GO:0035519; P:protein K29-linked ubiquitination; IDA:UniProtKB.
DR   GO; GO:0085020; P:protein K6-linked ubiquitination; IDA:UniProtKB.
DR   GO; GO:0070534; P:protein K63-linked ubiquitination; IDA:UniProtKB.
DR   GO; GO:0016567; P:protein ubiquitination; TAS:Reactome.
DR   CDD; cd00195; UBCc; 1.
DR   Gene3D; 3.10.110.10; -; 1.
DR   InterPro; IPR000608; UBQ-conjugat_E2.
DR   InterPro; IPR023313; UBQ-conjugating_AS.
DR   InterPro; IPR016135; UBQ-conjugating_enzyme/RWD.
DR   Pfam; PF00179; UQ_con; 1.
DR   SUPFAM; SSF54495; SSF54495; 1.
DR   PROSITE; PS00183; UBIQUITIN_CONJUGAT_1; 1.
DR   PROSITE; PS50127; UBIQUITIN_CONJUGAT_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; ATP-binding; Cell cycle; Cell division;
KW   Complete proteome; Nucleotide-binding; Phosphoprotein;
KW   Reference proteome; Transferase; Ubl conjugation;
KW   Ubl conjugation pathway.
FT   CHAIN         1    222       Ubiquitin-conjugating enzyme E2 S.
FT                                /FTId=PRO_0000082507.
FT   ACT_SITE     95     95       Glycyl thioester intermediate.
FT   MOD_RES       1      1       N-acetylmethionine.
FT                                {ECO:0000244|PubMed:19413330}.
FT   MOD_RES     173    173       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MUTAGEN      95     95       C->S: Loss of function.
FT                                {ECO:0000269|PubMed:19822757,
FT                                ECO:0000269|PubMed:20622874}.
FT   CONFLICT    216    216       K -> KRAL (in Ref. 1; AAA58446).
FT                                {ECO:0000305}.
FT   HELIX        10     25       {ECO:0000244|PDB:1ZDN}.
FT   STRAND       31     35       {ECO:0000244|PDB:1ZDN}.
FT   STRAND       42     48       {ECO:0000244|PDB:1ZDN}.
FT   TURN         54     57       {ECO:0000244|PDB:1ZDN}.
FT   STRAND       59     65       {ECO:0000244|PDB:1ZDN}.
FT   TURN         68     72       {ECO:0000244|PDB:1ZDN}.
FT   STRAND       76     81       {ECO:0000244|PDB:1ZDN}.
FT   STRAND       92     94       {ECO:0000244|PDB:1ZDN}.
FT   HELIX        96     99       {ECO:0000244|PDB:1ZDN}.
FT   TURN        100    102       {ECO:0000244|PDB:1ZDN}.
FT   HELIX       109    121       {ECO:0000244|PDB:1ZDN}.
FT   HELIX       125    127       {ECO:0000244|PDB:1ZDN}.
FT   HELIX       131    139       {ECO:0000244|PDB:1ZDN}.
FT   HELIX       141    155       {ECO:0000244|PDB:1ZDN}.
SQ   SEQUENCE   222 AA;  23845 MW;  2842DC3DCD2AFCB5 CRC64;
     MNSNVENLPP HIIRLVYKEV TTLTADPPDG IKVFPNEEDL TDLQVTIEGP EGTPYAGGLF
     RMKLLLGKDF PASPPKGYFL TKIFHPNVGA NGEICVNVLK RDWTAELGIR HVLLTIKCLL
     IHPNPESALN EEAGRLLLEN YEEYAARARL LTEIHGGAGG PSGRAEAGRA LASGTEASST
     DPGAPGGPGG AEGPMAKKHA GERDKKLAAK KKTDKKRALR RL
//
